marketshareAI
Theme

GSK

GSKHealthcare
1,646.50GBX
-0.36%
Market Cap
66.19B
Volume
4.67k
0% of avg
P/E Ratio
980.06
EPS (TTM)
1.68
Beta
0.29
Day Range
0.00p - 0.00p
52 Week Range
0.00p1,646.50p1,684.50p
1,646.50p

Upcoming Events

December 2025
Expected marketing authorization for Shingrix prefilled syringe in the EU
December 2025
Potential Regulatory Approval
High Impact Event
December 16, 2025
PDUFA date for FDA review of depemokimab submissions
High Impact Event
Q4 2025
GSK plans to file tebipenem HBr data with US regulators
High Impact Event
1 January 2026
Luke Miels assumes full CEO responsibilities
High Impact Event
Early Q1 2026
Expected regulatory decision on Arexvy for adults 18 years and older
High Impact Event
2026
Launch of next-generation low carbon Ventolin MDI
High Impact Event
24 March 2026
PDUFA goal date for FDA decision on linerixibat NDA
High Impact Event
30 September 2026
Emma Walmsley's employment with GSK ends
2029
Potential first launch of efimosfermin
High Impact Event
Beyond 2031
Significant new growth opportunities for GSK
High Impact Event
2034
End of extended exclusive rights for Zhifei to commercialize Shingrix in China
High Impact Event
GSK
NEUTRAL

GSK announces positive data for low carbon Ventolin MDI

The healthcare company has announced positive data for a low carbon version of its Ventolin metered dose inhaler, which could reduce greenhouse gas emissions by 92% per inhaler.

GSK
NEUTRAL

GSK provides update on latozinemab trial

The pharmaceutical company has reported results from a clinical trial of its latozinemab drug, which did not meet the primary endpoint.

GSK
NEUTRAL

GSK's Shingrix Vaccine Gets Positive CHMP Opinion for Prefilled Syringe

The healthcare company received a positive opinion from the European regulator for a new prefilled syringe version of its shingles vaccine Shingrix.

GSK
NEUTRAL

GSK's Oral Antibiotic Tebipenem HBr Meets Primary Endpoint in Phase 3 cUTI Trial

The healthcare company announced positive Phase 3 data for its oral antibiotic tebipenem HBr, which demonstrated non-inferiority to an intravenous treatment for complicated urinary tract infections.

GSK
NEUTRAL

GSK Directors Increase Shareholdings

The pharmaceutical company's directors have increased their shareholdings in the business through the re-investment of dividends.

GSK
NEUTRAL

GSK Directors Increase Shareholdings

The major pharmaceutical company has announced an increase in shareholdings by its directors and senior executives.

GSK
NEUTRAL

GSK Expands Shingrix Approval in China to Immunodeficient Patients

The healthcare company has received expanded approval for its Shingrix vaccine in China, allowing it to be used in adults at increased risk of shingles due to immunodeficiency or immunosuppression.

GSK
NEUTRAL

GSK Directors Increase Shareholdings

The major pharmaceutical company's directors have increased their shareholdings in the company through the share reward plan.

GSK
NEUTRAL

GSK Announces Share Acquisitions by Directors and PDMRs

The pharmaceutical company has announced the acquisition of ordinary shares by several of its directors and PDMRs under the company's share reward plan.

GSK
NEUTRAL

GSK Announces Third Tranche of Share Buyback Programme

The major pharmaceutical company is continuing its previously announced share buyback programme with a new £0.3 billion tranche.